Pre-release: this release has not been published. Identifiers are permanent; descriptions may still change.

HB 5049 (2025-2026)

https://ontology.bommaritollc.com/id/01a0d569-bdb6-74a8-99e2-a31b526d3e7e

adms:identifier	mi-legislature-measure 2025-2026/HB/5049
dcterms:temporal	Michigan Legislature, 2025-2026 session
in committee	Senate Committee on Health Policy (2025-2026)
primary sponsor	Regina Weiss
prov:wasDerivedFrom	evidence from https://www.legislature.mi.gov/Bills/Bill?ObjectName=2025-HB-5049 evidence from https://www.legislature.mi.gov/Bills/Bill?ObjectName=2025-HB-5049
schema:legislationChanges	MCL 380.1179a
schema:legislationIdentifier	HB 5049
schema:legislationJurisdiction	Michigan
schema:legislationType	bill
schema:name	Health: pharmaceuticals; administration of epinephrine; modify. Amends sec. 1179a of 1976 PA 451 (MCL 380.1179a ). TIE BAR WITH: HB 5054'25 , HB 5050'25 , HB 5051'25 , HB 5052'25 , HB 5053'25en
schema:sponsor	Regina Weiss Mai Xiong Jason M Hoskins Morgan Foreman Nancy Jenkins-Arno Steve Frisbie Kathy Schmaltz Brenda Carter Mark A Tisdel Thomas Kuhn Alicia St. Germaine Joseph Pavlov Brian BeGole Penelope Tsernoglou Nancy DeBoer Will Snyder Luke Meerman Matthew Bierlein David Prestin Karl Bohnak
schema:url	https://www.legislature.mi.gov/Bills/Bill?ObjectName=2025-HB-5049
skos:prefLabel	HB 5049 (2025-2026)en
status	in committee
status date	2026-01-14xsd:date